Chronic Lymphocytic Leukemia: Slow-Appearing Symptoms

New therapies are transforming treatment

Chronic lymphocytic leukemia (CLL) is a bone marrow cancer leading to abnormal white blood cells in the blood. It’s slow-growing and mainly affects older adults. It can be years before chronic lymphocytic leukemia needs treatment, and treatments can keep the worst symptoms at bay for many years.

In this case, "chronic" means the cancerous cells are partially mature. The cancer cells look normal but don’t work as well and live longer than healthy cells. This cancer takes time to show symptoms.

tired woman on the bus

Marjan_Apostolovic / Getty Images

CLL is slow growing but very hard to cure. As the disease progresses, the defective cells grow and spread to the lymph nodes, liver, and spleen. A bone marrow transplant is the only cure but is not often the best treatment choice. Many people live with this cancer until they die of other causes.

This article will explain chronic lymphocytic leukemia, the symptoms and treatments, and what people can expect regarding life expectancy, survival, remission, and relapse rates. It will also advise on living with this slow-growing cancer with lifestyle, medical treatments, and ways to improve quality of life.

Acute vs. Chronic Lymphocytic Leukemia 

Chronic lymphocytic leukemia is just one of many types of leukemias (cancers of the white blood cells). Specifically, CLL differs from acute lymphoblastic leukemia because of how mature the cancer cells are. 

Leukemia Types

Leukemias are classified as myeloid or lymphocytic depending on what precursor cells the cancer starts in. Lymphocytic, lymphoid, or lymphoblastic leukemias start in the cells that become lymphocyte white blood cells. Myeloid leukemias begin in the bone marrow cells that become other types of white blood cells, red blood cells, and platelets.

Chronic leukemia cells mature partly and look more like normal white blood cells than other leukemia cells. Acute leukemias have cancer cells that look more immature, wild, and defective. Chronic leukemias are slow growing but are more complicated to cure than acute leukemias.

CLL often affects older adults. It’s rare in children but is the most common leukemia in adults—accounting for about 38% of new leukemia cases in adults. Estimates for 2023 suggest 18,740 new cases and 4,490 deaths from CLL. It is more common in men than women. The terms for sex or gender from the cited source are used.

Symptoms: Do I Have Chronic Lymphocytic Leukemia?

Most of the time, people diagnosed with chronic lymphocytic leukemia do not have symptoms. It’s often found based on blood tests done for other reasons.

The symptoms of chronic lymphocytic leukemia often are vague and are also symptoms of diseases other than cancer. Chronic lymphocytic leukemia symptoms include:

If you have these symptoms, abnormal blood tests, and are the right age for chronic lymphocytic leukemia, your healthcare provider will order tests to diagnose chronic lymphocytic leukemia

Tests include:

  • Complete blood count (CBC) test to measure many types of cells in your blood: Too many lymphocytes are a sign of chronic lymphocytic leukemia.
  • Test of the cells in the bone marrow: A healthcare provider samples the tissue with a needle, and a pathologist checks it for leukemia cells.
  • The pathologist may also check other blood, bone marrow, and lymph node samples to determine the kind of leukemia.
  • Blood tests will check your liver, kidney, and other organ function.
  • Imaging tests, usually computed tomography (CT) scans, check for cancer in your lymph nodes, spleen, or liver.

Causes and Risk Factors

Most cases of chronic lymphocytic leukemia do not have a cause. Risk factors include older age, exposure to chemicals (research has linked exposure to Agent Orange herbicide, other pesticides, and radon to chronic lymphocytic leukemia), family history of leukemias, and sex.

Secondary Chronic Lymphocytic Leukemia Complications

Bone marrow in CLL makes new, abnormal lymphocytic white blood cells faster than usual. They live longer than they should and crowd out normal cells. As the body's abnormal white blood cells build up, so do the signs and symptoms of advanced CLL.

Red blood cell and platelet counts drop, and normal white blood cells die off. This can cause several complications, including:

  • Anemia: A lack of red blood cells causes tiredness, weakness, and shortness of breath.
  • Leukopenia: A lack of normal white blood cells increases infection risk. 
  • Neutropenia: A lack of healthy neutrophils (a type of white blood cell that usually is most numerous in the blood) increases infection risk.
  • Thrombocytopenia: A lack of platelets causes excessive bruising and bleeding (including severe nosebleeds and bleeding gums).

Many of these complications put people with CLL at a higher risk of infection. This might mean frequent colds, cold sore outbreaks, or a higher risk of developing illnesses like pneumonia (lung infection) or fungal infections.

The cancerous white blood cells in CLL may also make abnormal antibodies that attack normal blood cells—a complication known as autoimmunity. It may also cause autoimmune hemolytic anemia, in which the antibodies attack and destroy red blood cells.

As chronic lymphocytic leukemia advances, it can transform into more aggressive cancers that may be harder to treat, including:

Acute myeloid leukemia may develop due to treatment that damages myeloid white blood cell precursors rather than CLL transforming into it.

How Successful Is Chronic Lymphocytic Leukemia Treatment?

Many people with CLL do not die of it. Only about one-third need treatment. Many are older (the average age at diagnosis is 70), and often, because the cancer is slow-growing, they may die from other causes before needing treatment. In one-third to one-half of cases, infections may kill the person before the cancer does. 

If chronic lymphocytic leukemia advances and needs treatment, it can be tough to cure. But as new therapies are developed, many people can live years without their disease worsening. 

Staging and Risk Groups

Healthcare providers determine the best treatment options and prognosis for people with chronic lymphocytic leukemia based on the stage of their disease. Staging is a way of comparing cancers, treatments, and predictions and is determined during diagnosis. 

There are two different staging systems used for chronic lymphocytic leukemia. Doctors in the United States use the Rai system based on the number of lymphocytes in their blood and bone marrow.

The following stages are used for chronic lymphocytic leukemia:

  • In stage 0, the blood has too many lymphocytes in the blood, but there are no other signs or symptoms.
  • In stage 1, the excess of lymphocytes makes the lymph nodes more significant than usual.
  • In stage 2, the abnormal lymphocytes in the blood make the liver or spleen larger than usual.
  • In stage 3, there are too few red blood cells. The abnormal white cells have made the lymph nodes, liver, or spleen larger than usual.
  • In stage 4, the blood has too few platelets; the lymph nodes, liver, or spleen, are more significant than usual, or there are too few red blood cells.

Doctors separate the five Rai stages into low-, intermediate-, and high-risk groups.

  • Stage 0 is low risk.
  • Stages 1 and 2 are an intermediate risk.
  • Stages 3 and 4 are high risk.

The Binet staging system is more common in Europe. It classifies chronic lymphocytic leukemia by the lymphoid tissue groups affected. This includes the neck lymph nodes, groin lymph nodes, underarm lymph nodes, spleen, and liver. It also takes into account anemia and thrombocytopenia. The stages are A, B, and C, by how advanced the disease is.

Other Factors in Prognosis

Other factors play a role in a person's prognosis. Factors that negatively impact prognosis include:

  • Older age
  • Worse overall health 
  • Genetic changes, including deletions on chromosomes 17 or 11 or duplication of chromosome 12
  • High levels of the proteins ZAP-70 and CD38 in the cancer cells
  • Cancer that has spread to the spleen, liver, or lymph nodes
  • The presence of symptoms 
  • Cancer that has come back or has not responded to treatment
  • A higher volume of bone marrow has been replaced by cancer cells
  • High blood levels of beta-2-microglobulin
  • A lymphocyte count that doubles in less than one year
  • Higher levels of immature lymphocytes in the blood
  • An unchanged immunoglobulin heavy chain variable region (IGHV) on the cancer cells
  • Missing TP53 gene on the cancer cells

Delaying Chronic Lymphocytic Leukemia Treatment

As chronic lymphocytic leukemia progresses, it has four stages, as follows:

  • Asymptomatic, in which cancer causes no or few symptoms
  • Symptomatic or progressive, as cancer causes severe symptoms
  • Recurrent cancer that has come back after a period of remission
  • Refractory cancer does not get better with treatment

People with slow-growing low-risk CLL will not need treatment right away. Research has shown that treating this cancer early does not help people live longer. In the asymptomatic phase, healthcare providers will often wait on treatment and monitor the blood counts until the disease worsens or you start having bothersome symptoms.

Because people with chronic lymphocytic leukemia are usually older and CLL progresses slowly, one-third of people diagnosed with it will never need treatment.

About 88% of people over age 20 diagnosed with chronic lymphocytic leukemia are alive five years later. That doesn’t tell us much since many people with CLL will live years and years without even needing treatment. 

Veterans With CLL

Because of the potential link between Agent Orange and leukemias, veterans with chronic lymphocytic leukemia exposed to Agent Orange or other herbicides during military service are eligible to receive health care and disability compensation from the Department of Veterans Affairs.

After Diagnosis: Chronic Lymphocytic Leukemia Treatment Plan

Most people will wait on treatment until they have symptoms. When they need treatment, the first-line therapy for chronic lymphocytic leukemia has long been chemotherapy-immunotherapy. However, new targeted therapies have been developed. You may also need surgeries (like spleen removal) or radiation to reduce symptoms.

For many, treatment can prolong disease-free survival for many more years, even after they have symptoms and need treatment. New, targeted therapies called Bruton tyrosine kinase inhibitors significantly affect survival and quality of life.

Healthcare providers test new drugs and new drug combinations in clinical trials. Clinical trials should be a treatment option for anyone with chronic lymphocytic leukemia.

Researchers are still studying the impact of these targeted therapies on survival, but their impact seems significant. They can be used until they stop working, unlike chemotherapy, which is too toxic to be used for long periods. Studies have shown that:

  • After four years on Calquence (acalabrutinib), 88% of people were still alive.
  • After two years on Brukinsa (zanubrutinib), 94% of people were still alive.
  • After seven years on Imbruvica (ibrutinib), 78% of people were still alive.

In addition to new treatment options, there is a significant difference in survival based on the type and stage of chronic lymphocytic leukemia. CLL is classified into these two types:

  • The slow-growing type which low levels of ZAP-70 and CD38. People with this type may live for five to 10 years or longer.
  • The other kind has high levels of ZAP-70 and CD38, grows faster, and is a more severe disease. Those with very high-risk types may be referred for a stem cell transplant early in treatment, which can potentially cure the disease.

Chronic Lymphocytic Leukemia Remission Statistics 

For many, chronic lymphocytic leukemia treatment can be so effective that there are no signs of leukemia—known as complete remission. Though there is no cure, most people with CLL can undergo long periods of successful treatment without getting sicker.

But this disease often comes back at some point, so even if you’re in remission, it will not likely be a cure. Most people will relapse within the first five years of starting treatment. After first-line treatment with chemotherapy, 6% of cancers will return within 12 months, and another 14% will do so within two years.

Targeted therapies are more effective at prolonging progression-free survival than chemotherapy. Researchers are still studying the remission rates for these newer targeted therapies. How many people eventually relapse and require a new type of treatment is still unknown.

Self-Care With Chronic Lymphocytic Leukemia

Most people live with CLL for many years. About one-third will live out their lives and die from other causes without needing treatment. The rest will need treatment eventually, sometimes for years. Treatment, especially with chemotherapy, may stop for a while, but it never really ends.

Taking care of yourself during this time is essential. Living with cancer that will not likely be cured can be difficult and stressful. Remember that your healthcare team is there to help, and you can do your part by taking care of your body, such as in the following ways:

  • Your treatments may cause side effects: Tell your care team—they may be able to lower the dose or switch your treatment.
  • You may feel exhausted from your disease: Eat well and be active when you can. If you have anemia, your healthcare provider may recommend a transfusion.

Support for Advanced Chronic Lymphocytic Leukemia

Many people with cancer feel depressed, anxious, or worried. Though chronic lymphocytic leukemia can take a long time to progress, it can be hard to live with the threat of cancer returning or getting worse hanging over your head.

You can benefit from leaning on friends, family, and community and finding support groups, professional counselors, or others to help you cope on your cancer journey.

Know that many new drugs have been developed for this disease; ask your healthcare provider about clinical trials. New therapies for CLL are helping people, even those with advanced disease, live longer, often with a higher quality of life than other treatments.

Many people with chronic lymphocytic leukemia stay on these treatments—sometimes without their disease worsening—until they die of other causes.

Studies have shown that about one-third to one-half of people with chronic lymphocytic leukemia die from infections. Your healthcare provider can take steps to help you fight off infections. These may include vaccines, medicines like antivirals, or other treatments.

Other people with chronic lymphocytic leukemia die from the effects of the cancer cells on different parts of the body, which stop these organs from functioning normally.

Advanced chronic lymphocytic leukemia is hard to cope with when drugs are no longer working. You’ll need to decide which treatments are suitable for you.

Palliative care aims at reducing symptoms of cancer and its treatment and helping you reach your goals—whether that’s staying active or staying at home.

Summary 

Chronic lymphocytic leukemia is a type of blood cancer. It affects the bone marrow and causes an increase in abnormal lymphocytic white blood cells. It is most common in adults around age 70 and progresses slowly.

In CLL, the cancer cells occupy space and crowd out healthy cells. Symptoms of CLL can take a long time to appear. It's often discovered during tests for other reasons. Healthcare providers use blood, bone marrow, and imaging tests to diagnose CLL.

Chemotherapy and immunotherapy used to be the treatment of choice for CLL. Now, targeted therapies are usually the best option. 

Not all people need treatment immediately, especially if their CLL grows slowly and is low risk. Starting treatment early doesn't always improve survival rates. Instead, healthcare providers suggest watchful waiting, which is when your provider monitors you before starting treatment.

How long someone with CLL will live depends on their age, health, genetics of their cancer, and the cancer's stage. Many people with CLL don't die from the disease itself.

Living with CLL involves managing symptoms and treatment side effects and improving quality of life. Complications include anemia, a higher risk of infections, and abnormal antibodies. Regular checkups and maintaining a healthy lifestyle are essential.

19 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. American Cancer Society. What is chronic lymphocytic leukemia?

  2. American Cancer Society. Typical treatment of chronic lymphocytic leukemia.

  3. American Cancer Society. What Is chronic myeloid leukemia?

  4. American Society of Clinical Oncology. Leukemia - chronic lymphocytic - CLL: statistics.

  5. American Cancer Society. Key statistics for chronic lymphocytic leukemia.

  6. American Cancer Society. Signs and symptoms of chronic lymphocytic leukemia.

  7. American Cancer Society. If You Have Chronic Lymphocytic Leukemia (CLL) 

  8. American Cancer Society. Do we know what causes chronic lymphocytic leukemia?

  9. American Cancer Society. Risk factors for chronic lymphocytic leukemia.

  10. Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023;329(11):918-932. doi:10.1001/jama.2023.1946

  11. National Cancer Institute. Chronic lymphocytic leukemia treatment.

  12. American Cancer Society. Chronic lymphocytic leukemia stages.

  13. Department of Veterans Affairs. Chronic B-cell leukemias and Agent Orange - public health.

  14. American Cancer Society. What's new in chronic lymphocytic leukemia research and treatment?

  15. American Cancer Society. Living as a chronic lymphocytic leukemia survivor.

  16. LeukemiaCare. Relapse in chronic lymphocytic leukaemia (CLL).

  17. Collins S. 10 Years in CLL: top advances from 2012-2022. Targeted Therapies in Oncology. 2022;6:75-75.

  18. Crassini KR, Best OG, Mulligan SP. Immune failure, infection and survival in chronic lymphocytic leukemia. Haematologica. 2018;103(7):e329. doi:10.3324/haematol.2018.196543

  19. American Cancer Society. Supportive or Palliative Care for Chronic Lymphocytic Leukemia 

Jennifer Welsh Science and Health Writer Very Well

By Jennifer Welsh
Jennifer Welsh is a Connecticut-based science writer and editor with over ten years of experience under her belt. She’s previously worked and written for WIRED Science, The Scientist, Discover Magazine, LiveScience, and Business Insider.